Clinical Trial Update: Study of MDX-010 in Patients With Metastatic Hormone-Refractory Prostate Cancer [Phase 1, Phase 2]

View source ↗

Summary

This clinical trial update reports results from a phase 1/2 study of tremelimumab (MDX-010) in patients with metastatic hormone-refractory prostate cancer, with…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• MDX-010 (tremelimumab) (tremelimumab)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Prostate Cancer, Neoplasm Metastasis | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2014-08-28